Orphan Drug Development

The PPH Cure Foundation decided to deal with the challenge of developing existing medical compounds into approved medicines for PPH by encouraging the principal scientists behind Flolan to form a new biotech company focused on PPH and backed by a long-term contract from the Foundation. This new company, Lung Rx, Inc., was formed in August 1996 and is headed by Dr. James Crow, PhD, formerly of Glaxo-Wellcome. The mission of Lung Rx is to license from major pharmaceutical companies compounds that appear to have promise for arresting or reversing PPH, to conduct scientifically rigorous clinical trials to prove or disprove the safety and efficacy of these compounds, and to obtain regulatory approval to market the compounds to the international PPH community. We are hopeful that this new orphan drug company will expedite the clinical availability of PPH treatments.